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ABSTRACT  
Despite proven efficacy of alemtuzumab in multiple sclerosis (MS), approximately 
50% of individuals will develop a new autoimmune disease following treatment. To 
date these have largely been antibody mediated and organ specific (primarily 
affecting the thyroid gland). In a retrospective case series of 187 patients from two 
UK specialist centres (Cardiff and Cambridge) followed up for a median of 10 years, 
we report 3 (1.6%) cases of sarcoidosis following alemtuzumab treatment of MS. 
This report increases the spectrum of auto-inflammatory disease following 
alemtuzumab and should be considered by clinicians when using this therapeutic 
agent for MS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION  
Alemtuzumab is an effective treatment for relapsing multiple sclerosis (MS), 
reducing relapse rates and partially reversing neurological disability.1 However, 
approximately 50% of patients subsequently develop a secondary autoimmune 
disease (AID).1 Thus far, this has largely been antibody mediated and organ specific, 
for example 40% of individuals develop thyroid autoimmunity (most commonly 
Graves’ disease), 1-2% develop idiopathic thrombocytopenic purpura (ITP), and rare 
cases of Goodpasture’s disease and other autoimmune cytopenias have been 
described.2 Here we present three patients with MS, who developed systemic 
sarcoidosis following treatment with Alemtuzumab from two UK neuroscience 
centres. 
 
CASE REPORTS 
Case 1 
A previously healthy 42-year-old female was diagnosed with MS following two 
relapses and confirmatory paraclinical investigations (Table 1). Following further 
relapses and active repeat MR imaging, alemtuzumab treatment was commenced. 
This was administered as a standard treatment regime (initial treatment cycle 12 
mg/day intravenously for 5 consecutive days followed by 12 mg/day for 3 
consecutive days 12 months later). The patient experienced a further relapse 3 years 
and 8 months following first dose and an annual MR brain scan revealed an 
increased T2 lesion load, having been previously stable. A third treatment cycle (12 
mg/day for 3 days) was administered following which her disease has remained 
inactive.  
 Four years later she re-presented with a 6-month history of chest pain and shortness 
of breath. A chest X-ray (CXR) demonstrated bilateral hilar lymphadenopathy (Fig 
1a). A computed tomography pulmonary angiogram (CTPA) revealed bilateral hilar, 
right supraclavicular fossa, right paratracheal, left superior mediastinal and right 
axillary lymphadenopathy (Fig 1b). Ground-glass shadowing was also present. These 
changes were not present on a CTPA performed 4 years earlier for investigation of 
pleuritic chest pain. Respiratory examination was normal with oxygen saturations of 
97% on air. 
 
Repeat CT, performed after a 3 month interval demonstrated additional cervical, 
para-aortic and retroperitoneal lymphadenopathy. Peri-bronchovascular nodularity 
was also seen suggestive of lung parenchymal involvement (Fig 1c). Cervical lymph 
node biopsy demonstrated non-caseating granulomas and changes considered 
consistent with sarcoidosis (Fig 1d). The patient subsequently developed 
breathlessness, which improved with oral corticosteroids. Repeat CT imaging has 
shown improvement. Of note, serum angiotensin converting enzyme (ACE) has 
remained within the normal range. 
 
Case 2 
A previously healthy 38-year-old female was diagnosed with MS following two 
relapses and supporting investigations (Table 1). Three further relapses occurred and 
she was commenced on subcutaneous interferon beta-1a. However, over the 
following 22 months, she experienced 4 more relapses and was switched to 
natalizumab. She received 6 infusions but continued to experience frequent 
disabling relapses and was found to have neutralizing antibodies. Treatment was 
escalated to alemtuzumab, although 3 further relapses occurred during a planned 
washout period. Two courses of alemtuzumab were then administered according to 
the standard treatment regime 12 months apart with no further clinical relapses. 
 
Three years and 9 months after alemtuzumab induction she presented with 
menorrhagia and was diagnosed with idiopathic thrombocytopenic purpura (ITP) - 
platelets 22 x 109/L. At that time, CXR (Fig 1e) revealed incidental right-sided hilar 
lymphadenopathy. CT subsequently demonstrated bilateral hilar, mediastinal, 
axillary and supraclavicular lymphadenopathy (Fig 1f). Lung function tests were 
normal. Sub-carinal lymph node core biopsy showed granulomatous inflammation 
(Fig 1g and h) in association with a raised serum ACE (66 units/L, local reference 
range 8-52 units/L), which had previously been normal. Respiratory medicine review 
confirmed a diagnosis of sarcoidosis but no therapeutic intervention was considered 
necessary.  
 
Case 3 
A 20-year-old otherwise healthy male presented with diplopia and unsteadiness. 
Three months later the patient developed right-sided face and arm sensory 
symptoms and a diagnosis of MS was made with supporting radiological and 
biochemical findings (Table 1). Alemtuzumab was commenced at the standard 
treatment regime, with further courses given following clinical relapses; 3, 10 and 12 
years after initial treatment. Two years after the last treatment course, the patient 
reported fatigue, reduced exercise tolerance, exertional dyspneoa and arthralgia. 
Later that year, he experienced bilateral eye pain with a marked distortion of the 
right pupil. Intermittent anterior uveitis was diagnosed and treatment commenced 
with cyclopentamine and dexamethasone eye drops with complete resolution of eye 
symptoms. Further investigation revealed a raised serum ACE of 123 iu/L (local 
reference range 20-82 iu/L) with mediastinal lymphadenopathy on CXR and CT (Fig 1i 
and j). A transbronchial needle aspiration of hilar lymph nodes revealed granulomata 
typical of sarcoidosis (Fig 1k and l). As his symptoms were relatively mild, he 
continues to be actively monitored without systemic immunosuppression.  
 
Of note, all patients had a negative autoimmune screen at presentation and 
alternative diagnoses were excluded. All patients gave written consent for their case 
histories and images to be used in this manuscript. 
 
DISCUSSION  
Alemtuzumab, a humanised anti-CD52 monoclonal antibody, is an established 
treatment for active relapsing MS, with one phase II and two phase III trials 
confirming the marked effect on relapse frequency and slowing and/or reversing 
disability.1 Its main effect is to cause rapid depletion of peripheral B- and T- 
lymphocytes with repopulation occurring through proliferation of mature 
lymphocytes that escape deletion (‘homeostatic proliferation’) and later by thymic 
repopulation with naïve cells derived from CD52-negative haematopoietic 
precursors.1 This immune reconstitution is thought to be beneficial for disease 
outcomes.  
 Although having proven efficacy, secondary AID eventually occurs in approximately 
50% of patients, with the thyroid gland the most common target.3 Less commonly, 
patients may also develop ITP, haemolytic anaemia, autoimmune neutropaenia and 
glomerulonephritis.2 To date the vast majority of autoimmunity seen after treatment 
has been antibody mediated and organ specific, although cases of vitiligo, alopecia 
and more recently haemophagocytic syndrome have been described.4 Since 
alemtuzumab has only recently gained licensing approval, post-marketing 
surveillance remains essential to identify previously unrecognized adverse events 
and in particular those with potential autoimmune aetiology. 
 
Sarcoidosis is a systemic disease characterized by granuloma formation 
predominantly affecting the lungs and lymphatic system.5 The cause is unknown but 
an exaggerated cellular immune response to environmental stimuli such as 
mycobacteria and propionibacteria on a background of genetic susceptibility is 
considered likely. Through up-regulation of MHC class II molecules, alveolar 
macrophages are thought to act as antigen presenting cells with an influx of Th1 cells 
and absence of Tregs creating an unwanted inflammatory environment.5 These 
activated T cells release IL-2 and other chemotactic factors for blood monocytes 
leading to further recruitment of macrophages and establishing a recurring 
inflammatory cycle that leads to granuloma formation.6  
 
The development of sarcoidosis following alemtuzumab has only been reported once 
previously in the context of treatment for mycosis fungoides, an indolent T-cell 
cutaneous lymphoma.6 As suggested in that report,6 we postulate that our patients 
are likely to have developed sarcoidosis as a result of homeostatic proliferation 
predisposing to autoimmunity. In further support of sarcoidosis resulting from 
immune reconstitution is the observation that sarcoidosis associated with human 
immunodeficiency virus (HIV) has increased in the era of highly active antiretroviral 
therapy (HAART).7 Although neurosarcoidosis may have explained the initial 
presentation in these patients, we feel this is very unlikely and remain confident of 
the initial diagnosis of MS. 
 
Although we have demonstrated a frequency of 1.6% for sarcoidosis in our cohort, 
this was not identified as a notable adverse event in either the phase II or phase III 
studies. The reasons for this remain unclear, however, the unique clinical 
characteristics of this cohort collated over 16 years, together with the length of 
follow-up may be relevant. Although there is a theoretical potential for sarcoidosis 
to have been unconnected to treatment with alemtuzumab, the plausible biology 
and frequency makes this unlikely.  In addition to immune reconstitution, affected 
patients may also have been genetically susceptible and have been exposed to 
relevant environmental stimuli. Alemtuzumab has also recently been associated with 
monocytic/macrophage activation in the context of a patient with neuromyelitis 
optica;8 following treatment, massive central nervous system infiltration of 
monocyte/macrophage infiltration was observed. As macrophages are a key 
component of sarcoidosis pathology, activation of these cells in certain at-risk 
patients may also contribute to disease pathogenesis. 
 
Whilst the majority of observed autoimmune disease after alemtuzumab has been 
associated with the generation of antibodies, these cases highlight that other forms 
of autoimmunity can occur following treatment and should be considered as 
potential adverse events. 
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